Neuropacs provides an AI‑powered, cloud‑based imaging platform that automatically detects neurodegenerative disease signatures and quantifies progression markers from standard MRI and other scans. The software delivers precise diagnostic outputs—up to 96% accuracy for distinguishing Parkinson’s disease from related disorders—to enable reliable patient stratification and objective efficacy assessments in clinical trials and research settings.
Funding
Funding not disclosed
Founders
Product
Problem
Neurodegenerative clinical trials often struggle with inconsistent imaging biomarkers, making it difficult to detect disease onset, quantify progression, and select appropriate participants. This variability can delay therapy development and reduce the statistical power of trial endpoints.
Solution
Neuropacs™ offers an AI‑powered, cloud‑based imaging platform designed specifically for neurodegenerative diseases. The system processes standard MRI and other neuroimaging data to automatically detect disease signatures and generate quantitative progression markers. By providing highly precise diagnostic outputs—up to 96% accuracy in distinguishing Parkinson’s disease from multiple system atrophy and progressive supranuclear palsy—the platform enables reliable patient stratification and objective efficacy assessments. Integrated into existing imaging workflows, Neuropacs™ delivers actionable insights through secure dashboards, supporting both clinical decision‑making and trial endpoint optimization.
Target Audience
Primary customers are pharmaceutical companies, biotech firms, and contract research organizations conducting neurodegenerative disease trials, as well as academic medical centers that require advanced imaging analytics for patient selection and outcome measurement.
Features
- AI algorithms trained on large neurodegenerative cohorts to detect disease presence and differentiate subtypes
- Automated quantification of neurodegeneration markers for longitudinal efficacy monitoring
- Cloud‑hosted analysis pipeline that integrates with standard PACS and imaging workflows
- Secure web dashboard presenting diagnostic reports, progression metrics, and stratification recommendations
- High classification precision (up to 96%) for Parkinson’s disease versus MSA‑P and PSP
- Scalable SaaS deployment allowing rapid onboarding for multiple trial sites